The MHRA reported that, in a rare combination of blood clots with low platelet counts, 209 cases, including 41 deaths, had been recorded in the UK by 21 April. The total number of cases reported a week earlier was 168, including 32 deaths.
According to the age distribution, 23 cases occurred in the 18-29 age group, 27 in their thirties, 30 in their forties, 59 in their fifties, and 58 in the 60s and over.
In the remaining cases, the age was unknown. In the United Kingdom, about 7 million people in their 50s received the first dose of Covid-19, while about 5.5 million people under the age of 45 received the first dose.
The data indicate that younger adults have a higher incidence, and the MHRA recommends that you take this into account when considering vaccine use.
The organization said.
The agency that advises the UK government on the use of AstraZeneca, the Vaccination and Immunization Commission, is currently considering whether to change its guidance to offer an alternative to AstraZeneca for people under the age of 40.
On the one hand, there are concerns about the deaths associated with the vaccine, and on the other hand, there is the possibility of deaths due to slowing down the introduction of the vaccine.
This was said by Sir Munir Bir Muhammad, Chairman of the British Government Vaccine Safety Advisory Committee
Age is the only risk factor for blood clotting that has been identified so far, and young adults are “more susceptible” to rare side effects, which are fatal in about one-fifth of cases.
These special types of blood clots resulting from the AstraZeneca vaccine are still extremely rare and unlikely. Still, for most people, the benefits of the vaccine outweigh its risks.
Dr. John Wren, CEO of MHRA said.
Cover photo: Pier Marco Tacca / Getty Images